Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease

Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714 Amgen Will Invest $20 Million in Provention Equity Amgen Will be Responsible for Clinical Trial Supply and Manufacturing THOUSAND OAKS, Calif. and OLDWICK, N.J., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015. AMG 714 is a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (NRCD). Development efforts at Provent...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news